Novilla Pharmaceuticals

Novilla Pharmaceuticals is a Cambridge, Massachusetts biotech using a proprietary AI drug-delivery platform to redesign how established drugs reach the body. By pairing chemical-thermodynamic machine learning with deep eutectic solvents and ionic liquids, Novilla formulates non-invasive transdermal creams that concentrate a drug at its site of action while minimizing systemic exposure. Its lead candidate, NOV-1776 for gout flares, reported a 212% increase in efficacy over standard of care with under 1% systemic exposure and no GI adverse events in early human trials, positioning the company as a non-addictive alternative in pain care.